CHICAGO / Apr 18, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch of the Tempus Advisory Board. The Tempus Advisory Board is a vital resource for the company in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization. This group of engaged medical professionals... Read more
Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection. SAN ANTONIO / Apr 17, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer, today announced implementation of key efficiency measures for its flagship product, CyPath® Lung,... Read more
Strategic partnership expands Dario's employer footprint and has already started contributing to recurring revenues in Q1 of 2025 NEW YORK, April 17, 2025 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new strategic partnership with a leading benefit administrator to deliver its comprehensive cardiometabolic solution including a GLP-1 support program and full AI-driven digital... Read more
European certification for PD-L1 IHC 22C3 pharmDx to help gastric or GEJ adenocarcinoma patients for KEYTRUDA® therapy SANTA CLARA, Calif. / Apr 17, 2025 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible... Read more
157 patients enrolled
Topline results expected to be released in August 2025
Company to host Corporate Update Call on May 15, 2025 TORONTO, April 16, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the completion of full enrollment in the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use... Read more
The acquisition will unite complementary leading AI-powered cancer detection and workflow solutions focused on improving the accuracy and early detection of breast cancer
The transaction is expected to add to RadNet’s wholly owned subsidiary, DeepHealth, an installed base of over 1,500 healthcare provider locations across over 50 countries
With iCAD’s seasoned commercial and engineering team anticipated to join DeepHealth, the combination is expected to accelerate... Read more
Collaboration accelerates insights on clinical benefits of molecular profiling across all major categories of disease SAN DIEGO and CHICAGO, April 15, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) and Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation.... Read more
Three new innovative instrument launches expand reach into further lab segments and sample preparation customers as QIAGEN strengthens market-leading position
QIAsymphony Connect set to start phased launch in 2025, first customer sessions being held to highlight enhanced capabilities for oncology and genomics workflows
QIAsprint and QIAmini on track for 2026 launches, expanding options for high- and low-throughput lab demands VENLO, Netherlands / Apr 15, 2025 / Business... Read more
Comprehensive review confirms that the Oncotype DX Breast Recurrence Score® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity MADISON, Wis. / Apr 14, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX... Read more
Dexcom G7 15 Day* is now cleared in the US for people age 18 years and above with diabetes.
Now the longest lasting*,†,1 and most accurate1 CGM system, Dexcom G7 15 Day gives users the knowledge to better control diabetes.
For people between the ages 2 to 18, Dexcom G7 remains the most accurate2 continuous glucose monitoring system. SAN DIEGO / Apr 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the... Read more
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, today announced that the American Society of Clinical Oncology (ASCO) has accepted Telo Genomics' abstract submission regarding a concordance analysis between blood and marrow samples, using the TeloView® Minimal Residual... Read more
Implements Plan to Reduce Annualized Operating Expense Run Rate by $45 Million to $50 Million
Q1 2025 Earnings Conference Call Scheduled for May 8, 2025 MENLO PARK, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2025.
Preliminary First Quarter Results
Preliminary Q1 2025
Q1 2024 Revenue
$36.9 million
$38.8 million Instrument... Read more
In an oral presentation at the 2025 AAN Annual Meeting, Quest scientists presented data suggesting the test can accurately assess Alzheimer's disease pathology with greater than 90% sensitivity and specificity SECAUCUS, N.J., April 9, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to help physicians... Read more
Second major healthcare employer signs with DarioHealth, accelerating growth in 2025 and reinforcing its leadership in AI-powered, clinically validated digital health solutions for chronic condition management NEW YORK, April 8, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced a new employer partnership with one of the nation's most respected research and medical institutions.... Read more
SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM,... Read more
New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These appointments were part of a planned Board... Read more
Sea's pre-clinical stage neurotherapeutic synthetic oral molecules act at the neurotransmitter glutamate pathway on two clinically validated targets in the CNS (central nervous system) Sea's lead molecule SPM-0404 is a potential new oral treatment in investigational new drug (IND)-enabling studies for constant bothersome tinnitus, epilepsy, and sporadic ALS (S-ALS) Pre-clinical development work by Inotiv, Inc. to support Sea filing IND application at FDA... Read more
Q1 2025 preliminary net sales rise 7% CER and adjusted diluted EPS results of at least $0.55 CER both above outlook despite challenging macro environment Full-year 2025 adjusted diluted EPS outlook raised to about $2.35 CER (prior outlook about $2.28 CER) On track to exceed 31% CER adjusted operating income margin ahead of 2028 mid-term target VENLO, Netherlands / Apr 06, 2025 / Business Wire / QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced... Read more
Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee.
Mr. Farlinger is a veteran venture and private equity... Read more
With the addition of the Pounce™ XL Thrombectomy System, indicated for use in 5.5–10 mm peripheral arteries, the fully mechanical Pounce™ Thrombectomy Platform can now remove thrombi or emboli throughout the lower and upper extremities without aspiration, thrombolysis, or capital equipment EDEN PRAIRIE, Minn. / Apr 03, 2025 / Business Wire / Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care... Read more
Consistent with prior studies, published results from Castle’s DECIDE study show DecisionDx-Melanoma can both accurately identify patients with less than 5% risk of sentinel lymph node (SLN) positivity, who can safely consider forgoing the sentinel lymph node biopsy (SLNB) surgical procedure, and who are also unlikely to experience disease progression1,2
As of the last follow-up, all of the patients in the third study analysis with a low-risk DecisionDx-Melanoma test... Read more
FDA approves leading solution for latent tuberculosis diagnostics, advancing global effort to fight infectious diseases WALTHAM, Mass. / Apr 02, 2025 / Business Wire / Revvity, Inc. (NYSE: RVTY), today announced that the U.S. Food and Drug Administration (FDA) has approved the Auto-Pure 2400 liquid handling platform with the T-SPOT™.TB test. Initially launched outside the U.S. in 2024, this powerful combination allows laboratories to improve productivity while maintaining... Read more
Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection
Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening
New solution follows company's launch of GTI self-collection option... Read more
Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test... Read more
Two posters will share data on the significant risk stratification provided by DecisionDx-Melanoma in a real-world cohort of patients with stage IIB-IIC cutaneous melanoma (CM) to help guide adjuvant therapy, and the role of the test in prompting use of imaging surveillance in early-stage patients at high risk of metastasis to the central nervous system (CNS) FRIENDSWOOD, Texas, April 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving... Read more
Company Revamps Pharmacogenomics Go-To-Market Strategy, Targets Validated PGx Assay Towards Specific Use Cases STONY BROOK, NY / ACCESS Newswire / April 1, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), its wholly-owned clinical laboratory subsidiary, is repositioning its TR8™ PGx pharmacogenomics testing service to offer tailored subpanels... Read more
BURNABY, British Columbia / Apr 01, 2025 / Business Wire / As of today, the Government of Saskatchewan’s expanded public coverage for continuous glucose monitoring (CGM) systems comes into effect. Dexcom, Inc. (NASDAQ: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, applauds this decision as a testament to the government’s commitment to improving diabetes care. The expansion, which now provides full coverage for continuous... Read more
News Summary Boosts out-of-the-box sensitivity by up to 80 times with MaxPeakTM Premier columns.1
Delivers over threefold improvements in day-to-day reproducibility2 and decreases carryover by up to two orders of magnitude.3
Reduces common user errors by up to 40%.4 MILFORD, Mass., April 1, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the expansion of the Alliance™ iS Bio HPLC product line with integrated photodiode array (PDA) detection,... Read more
Malaria remains a major global health threat, with more than 250 million cases and 600,000 deaths in 2024 – over 90% of them in Africa
QIAprep& Plasmodium Kit enables streamlined detection of five malaria-causing parasites for epidemiological research and surveillance
Novel QIAGEN assays support mixed-infection tracking, vaccine impact assessment and malaria control strategies in regions with limited healthcare infrastructure VENLO, Netherlands / Apr 01, 2025... Read more
FT. MYERS, Fla. / Apr 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in healthcare.
“Tony has... Read more
Lab network revenue increased by 33% year over year, reflecting strong demand for ColoAlert® in Europe
Operating loss decreased by 30% and net loss by 18%, driven by targeted cost reductions and a sharper strategic focus
Strategic partnerships with industry leaders mark key progress
Company highlights its early accomplishments for 2025 BERKELEY, Calif. and MAINZ, Germany, April 01, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or... Read more
SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended December 31, 2024 and revenue outlook for 2025.
“2024 has been an important year for Bionano. Despite a challenging external environment with shrinking capital budgets, financial uncertainty for our customers and difficult equity capital markets, we have continued serving our mission of transforming the way the... Read more
Increased Demand, Expanded Insurance Coverage Drive Record Growth SAN ANTONIO / Mar 31, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2024.
2024 Highlights Record Revenue: Revenue grew approximately 270% to $9.4 million in 2024,... Read more
MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, announced that Evernorth Health Services, a wholly owned subsidiary of The Cigna Group, has expanded its coverage of NeuroStar® Transcranial Magnetic... Read more
Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases... Read more
Collaboration to enable cost-effective end-to-end genotyping across large animal and plant populations
Companies to present poster at AGBT-Ag SOUTH SAN FRANCISCO, Calif. & ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, and Curio Genomics, a pioneer in genomics software, today announced a collaboration to accelerate... Read more
The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test reported in studies to date MADISON, Wis. / Mar 31, 2025 / Business Wire / Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the launch of Cologuard Plus™, the most accurate noninvasive colorectal cancer screening (CRC) test reported in studies... Read more
Vancouver, British Columbia--(Newsfile Corp. - March 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, today announced the successful closing of its previously announced oversubscribed non-brokered private placement.
The closing of the second and final tranche builds upon the momentum of the previously announced first tranche on March 26, 2025, culminating in... Read more
Conference call to discuss financial and operational results scheduled for Monday, March 31 at 4:30 p.m. U.S. Eastern Time HENDERSON, Nevada, March 31, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024. Volition management will host a conference call today, March 31 at... Read more
ANN ARBOR, Mich. / Mar 31, 2025 / Business Wire / ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update.
Business Update
ENDRA made significant progress against many of the new initiatives discussed during the Company’s August 22, 2024, conference call to advance its TAEUS Liver device along the development... Read more
CHICAGO / Mar 29, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the company is scheduled to exhibit 4 abstracts at the American College of Cardiology (ACC) Annual Meeting, which convenes from March 29-31 in Chicago, Illinois. This is the first year that Tempus is presenting research, all of which highlights the application of AI to support clinicians in... Read more
New, combined validation cohort of 1,412 patients with high-risk squamous cell carcinoma (SCC) demonstrates that the addition of DecisionDx-SCC to Brigham & Women's Hospital (BWH) staging significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by National Comprehensive Cancer Network (NCCN) guidelines to support improved, risk-aligned treatment pathway decisions
Castle will also present new data showing DecisionDx®-Melanoma... Read more
Studies demonstrate how Volition's Nu.Q®H3K27Me3 biomarker, when combined with ctDNA, may improve the prognostic value for overall survival and could help inform treatment decisions in NSCLC; and how Volition's Nu.Q® H3.1, low-cost immunoassay may be utilized for the early identification of subjects at high risk of cancer HENDERSON, Nev., March 28, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics... Read more
MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press release to update the reporting of its financial results for the fourth quarter and full year ending December 31, 2024. Following the Company’s press release on March 4, 2025 initially issuing the Company’s fourth quarter and full year 2024 financial results (the “Initial Release”) and in connection with finalizing the... Read more
SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024.
Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue... Read more
2,000+ Average-Risk Patient Study Seeks to Confirm Mainz Biomed’s Industry-Leading Results in the Detection of Advanced Precancerous Lesions (APL) in Independent Samples
Study is on Track to Report Top-Line Results in Fourth Quarter 2025 BERKELEY, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today... Read more
TORONTO, March 27, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2024 and provided a corporate update.
The Company made significant progress throughout 2024, both clinically and operationally. Specifically, regarding its Tigris trial,... Read more
Record 2024 OvaSuite revenue of $9.2 million and volume of 24,305 units sold AUSTIN, TX / ACCESS Newswire / March 27, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2024. Select financial results are as follows:
Fourth Quarter 2024 and Recent... Read more
Case Demonstrates Benefit of Integrating CyPath® Lung into Standard of Care for Patients Under Surveillance After Treatment for Previous Lung Cancer SAN ANTONIO / Mar 26, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) today released a case study in which a positive CyPath® Lung result led to the detection of a second primary lung cancer in a high-risk patient who was previously diagnosed with stage 1A non-small cell lung cancer and underwent... Read more
STONY BROOK, NY / ACCESS Newswire / March 26, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that Applied DNA Clinical Labs (ADCL), the Company's wholly-owned clinical laboratory subsidiary, has submitted a validation package to the New York State Department of Health (NYSDOH) to request approval as a laboratory-developed test (LDT) for a PCR-based assay for the detection and subtyping... Read more
